Hormone replacement therapy: PRAC completes review of new information on known breast cancer risk
2020.05.15
Active substance: substances for hormone replacement therapy
The Committee for Pharmacovigilance Risk Assessment (PRAC) of the EMA recommends updating the current safety information of medicinal products for HRT, in relation to the known increased risk of breast cancer.
To the risk information (available in German only)